Abstract | RATIONALE: METHODS: In conjunction with a placebo controlled, randomized clinical trial, a cost effectiveness analysis was carried out to assess the economic impact of using OM-85 BV. In the analysis, effectiveness was defined as the difference in the number of severe acute exacerbations, assessed by the number of hospitalizations for a respiratory problem, between the placebo and OM-85 BV-treated groups. RESULTS: The median cost to prevent one day of hospitalization for a respiratory condition was CDN$45, with a 95% CI of CDN$18 to CDN$210. Bootstrap of the study population and sensitivity analyses showed that the results were robust and not likely due to random fluctuation; 98.8% of the cost effectiveness and 96.8% of the cost-benefit ratios favoured the use of OM-85 BV. Indirect costs, defined as a need for help, were reduced by 36% in the group treated with OM-85 BV: 779 h of help compared with 1212 h in the placebo group. This trend, while not significant, is consistent with other results and suggests a decrease in the severity of exacerbations in the OM-85 BV-treated group. CONCLUSION:
|
Authors | J P Collet, T Ducruet, S Haider, S Shapiro, A Robinson, P M Renzi, A P Contandriopoulos, P Ernst |
Journal | Canadian respiratory journal
(Can Respir J)
2001 Jan-Feb
Vol. 8
Issue 1
Pg. 27-33
ISSN: 1198-2241 [Print] Egypt |
PMID | 11223497
(Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Adjuvants, Immunologic
- Broncho-Vaxom
- Cell Extracts
|
Topics |
- Adjuvants, Immunologic
(administration & dosage, economics, therapeutic use)
- Bacteria
- Cell Extracts
- Cost-Benefit Analysis
- Female
- Health Care Costs
- Humans
- Length of Stay
(economics)
- Lung Diseases, Obstructive
(drug therapy, economics)
- Male
- Prevalence
- Severity of Illness Index
- Treatment Outcome
|